radloop®’s Post

Our incoming ECCV 2024 paper "Effective Lymph Nodes Detection in CT Scans Using Location Debiased Query Selection and Contrastive Query Representation in Transformer"and MICCAI 2024 paper "Slice-Consistent Lymph Nodes Detection Transformer in CT Scans via Cross-slice Query Contrastive Learning", by Yirui Wang Dakai Jin Ke Yan Dazhou Guo are making solid progresses on detecting, localizing and identifying lymph node anomaly using 3D CT scans from (all) body parts. Lymph node (LN) assessment is a critical, indispensable yet very challenging task in the routine clinical workflow for radiology/oncology. Accurate LN analysis is essential for cancer diagnosis, staging and treatment planning. Finding scatteredly distributed, low-contrast clinically relevant LNs in 3D CT is difficult even for experienced physicians under high inter-observer variations. We propose a new LN DEtection TRansformer, named LN-DETR, to achieve more accurate performance. By enhancing the 2D backbone with a multi-scale 2.5D feature fusion to incorporate 3D context explicitly, more importantly, we make two main contributions to improve the representation quality of LN queries. 1) Considering that LN boundaries are often unclear, an IoU prediction head and a location debiased query selection are proposed to select LN queries of higher localization accuracy as the decoder query’s initialization. 2) To reduce FPs, query contrastive learning is employed to explicitly reinforce LN queries towards their best-matched ground-truth queries over unmatched query predictions. Trained and tested on 3D CT scans of 1067 patients (with 10000+ labeled LNs) via combining seven LN datasets from different body parts (neck, chest, and abdomen) and pathologies/cancers, our method significantly improves the performance of previous leading methods ... https://lnkd.in/eqJaBGye

Treatment option for recurrent glioblastoma: Radiosurgery+Bevacizumab Glioblastoma (GBM) is acknowledged as the most malignant brain tumor, while high-grade gliomas, despite their rarity in adults, represent the most prevalent primary brain tumors, accounting for 2% of all adult cancer cases. Despite employing multidisciplinary approaches involving surgery, radiotherapy, and chemotherapy, the survival rates for GBM remain discouraging. The established 2005 protocol, derived from a pivotal randomized clinical trial, advocates maximal surgical resection followed by concomitant chemoradiation with temozolomide (TMZ). However, recurrence emerges as an inevitable reality for the majority, with a notable 75–80% of cases experiencing local recurrence, significantly impacting survival rates. Interestingly, only a small percentage manifests in anatomically distant sites, such as the contralateral hemisphere (4%). This retrospective review included 95 recurrent GBM patients, among whom 19 received bevacizumab only (BEV Only), 57 were treated with both bevacizumab and Gamma Knife (BEV + GK), and 19 underwent Gamma Knife stereotactic radiosurgery only (GK Only). Results: - The median progression-free survival (PFS) and overall survival (OS) were 14.1 months and 17.1 months, respectively. - The BEV + GK group exhibited the highest median PFS (BEV Only vs. BEV + GK vs. GK Only: 11.8 vs. 15.6 vs. 12.0 months, p = 0.015). - The BEV + GK OS also showed improvement (BEV Only vs. BEV + GK vs. GK Only: 14.3 vs. 18.6 vs. 15.0 months, p = 0.0050). - Patients in the combination treatment group also demonstrated significantly enhanced post-tumor recurrence PFS and OS compared to those receiving individual treatments (Post-Recurrence PFS, BEV Only vs. BEV + GK vs. GK Only: 5.0 vs. 7.7 vs. 4.9 months, p = 0.018; Post-Recurrence OS, BEV Only vs. BEV + GK vs. GK Only: 6.5 vs. 11.5 vs. 7.9 months, p = 0.0082). Conclusions: This retrospective study indicates that the combined utilization of bevacizumab and Gamma Knife in recurrent glioblastoma patients enhances progression-free and overall survival compared to monotherapy with either bevacizumab or Gamma Knife alone. These findings align with previous literature suggesting that a combined regimen of an antiangiogenic agent with stereotactic radiosurgery may improve survival in recurrent disease. However, a prospective randomized study is warranted in the future to conclusively address this question. https://lnkd.in/dQb3v_CQ #oncology #neurooncology #radiationoncology #radiotherapy #radiosurgery #radonc #neurology #glioblastoma #GBM

Our recent review paper emphasizes the crucial partnership between radiation oncologists and dental specialists. Learn how proactive measures and post-treatment follow-up can minimize oral complications for better patient outcomes. #headandneck #cancer #HNC #RadiationTherapy #radiotherapy #IMRT #IMPT #proton #radiation #DentalSpecialists #Collaboration #PatientOutcomes #qualityoflife #radiationoncology #oncology #dentist #education #miamicancerinstitute #baptisthealth

Great news in #breastcancer research! An FDA (U.S. Food and Drug Administration) advisory committee has given the green light for a new agent in Lumicell’s breast cancer imaging tool. The FDA has deemed its benefits to outweigh the risks. This tool could revolutionize breast cancer surgery by detecting residual cancer in real-time, potentially reducing the need for additional procedures. To read and learn more in-depth, click below: https://lnkd.in/gangnZHr - MedTech Dive Advanced Biomedical Repair #BecauseYourNextInspectionMatters . . . . #MedicalInnovation #MedicalDevice #MedicalDevices #Innovation #medicaldevices #expert #experts #surgery #healthtech #SouthernCalifornia #Ventura #SanLuisObispo #Atascadero #VenturaCounty #Fresno #CentralCalifornia #NorCal #healthcare #medhealth #breastcancerawareness #breastcancersurvivors #breastcancertreatment #breastcancerresearch

📃Scientific paper: Evaluation of surgical outcomes and prognostic factors of second primary lung cancer based on a systematic review and meta-analysis Abstract: Background Although surgery has been widely applied for SPLC therapy, there is still no uniform treatment approach. Whether SPLC and primary lung cancer have similar prognostic characteristics remains controversial. Herein, based on a systematic review and meta-analysis, we aimed to enucleate the influences of diverse surgical strategies and underlying prognostic factors on the prognosis of patients with both the first primary lung cancer and SPLC underwent surgical resection. Methods A comprehensive and systematic literature search was implemented in three databases (MEDLINE, EMBASE, and Cochrane), and eligible studies were screened following inclusion and exclusion criteria. Meanwhile, we extracted the hazard ratios (HR) together with 95% confidence intervals (CI) for each prognostic factor, either directly or indirectly, from the enrolled literature. Results Eleven studies (published between 2000 and 2022) were included in this study, including 1,131 SPLC patients. The overall survival (OS) exhibited no difference between patients with lobectomy and sublobar resection after SPLC (HR: 0.87, 95%CI: 0.62–1.21, P  = 0.41). The patients after completion pneumonectomy had a poor prognosis (HR: 1.85, 95% CI: 1.34–2.55, P  < 0.01). Poor prognostic factors after SPLC surgery included synchronous SPLC (HR: 3.38, 95%CI: 1.53–7.46, P  < 0.01), tumor diameter > 2 cm (HR: 2.44, 95%CI: 1.73–3.44, P  < 0.01), solid predominant in CT morphology (HR: 3.08, 95% CI: 1.14–8.33, P  = ... Continued on ES/IODE ➡️ https://etcse.fr/1gZl ------- If you find this interesting, feel free to follow, comment and share. We need your help to enhance our visibility, so that our platform continues to serve you.

Intraoperative assessment of anastomotic blood supply using indocyanine green fluorescence imaging following esophagojejunostomy or esophagogastrostomy for gastric cancer Objective: This retrospective study aimed to evaluate the feasibility and safety of intraoperative assessment of anastomotic blood supply in patients undergoing esophagojejunostomy or esophagogastrostomy for gastric cancer using Indocyanine Green Fluorescence Imaging (IGFI). Materials and methods: From January 2019 to October 2021, we conducted a retrospective analysis of patients who had undergone laparoscopic gastrectomy for the treatment of gastric cancer. The patients were consecutively enrolled and categorized into two study groups: the Indocyanine Green Fluorescence Imaging (IGFI) group consisting of 86 patients, and the control group comprising 92 patients. In the IGFI group, intravenous administration of Indocyanine Green (ICG) was performed, and we utilized a fluorescence camera system to assess anastomotic blood supply both before and after the anastomosis. Results: The demographic characteristics of patients in both groups were found to be comparable. In the IGFI group, the mean time to observe perfusion fluorescence was 26.3 ± 12.0 seconds post-ICG injection, and six patients needed to select a more proximal resection point due to insufficient fluorescence at their initial site of choice. Notably, the IGFI group exhibited a lower incidence of postoperative anastomotic leakage, with no significant disparities observed in terms of pathological outcomes, postoperative recovery, or other postoperative complication rates when compared to the control group (p > 0.05). Conclusion: This study underscores the potential of IGFI as a dependable and pragmatic tool for the assessment of anastomotic blood supply following esophagojejunostomy or esophagogastrostomy for gastric cancer. The use of IGFI may potentially reduce the occurrence of postoperative anastomotic leakage. #igfi #icg #indocyaninegreen #verdye #gasticcancer #fluorescenceguidedsurgery #fgs #diagnosticgreen

🔍 EXCITING FINDINGS! 🔍 Radiologist Consultation Proven to Enhance Patient Attitudes Towards Lung Cancer Screenings! Delighted to share this groundbreaking article from AuntMinnie.com shedding light on the invaluable role of radiologists in shaping patient perspectives on lung cancer screenings. The study underscores the significant impact of radiologist consultations in not just improving patient understanding but also positively influencing their attitudes towards screenings. Check out the full article here: https://lnkd.in/gnWBYjdf Kudos to the team at The University of Chicago Pritzker School of Medicine who conducted this research for their dedication to enhancing patient care and awareness in lung cancer screening. Let's continue to collaborate and innovate to empower patients to take charge of their lung health! #Radiology #PatientCare #LungCancerScreening #HealthcareInnovation #pulmonology

📝 Evaluating Surgical Outcomes and Survival in Colon Cancer Patients Over 80 Years Old 📝 ⬆ A Portuguese study aimed to analyze the surgical outcomes and survival of patients over 80 years old undergoing surgery for colon cancer. 🔹 Patients: 90 total, 41.1% female 🔹 Median Charlson Comorbidity Index: 7.0 🔪 Surgical Details: - Elective Surgeries: 73% - Laparoscopic Surgery: 66.7% - Adjuvant Chemotherapy only in 8.3%. ⚠️ Emergent admissions associated with advanced cancer stages, ⬆ open surgeries and ⬆ postoperative mortality. 🌟 Key Takeaway: Patients undergoing elective surgeries show significantly better survival rates compared to emergent cases. No significant differences in survival between elective and emergent groups among those receiving curative-intent procedures. Congratulations to Jorge R. Rodrigues Ana Sofia Cavadas and co-workers for this interesting piece of data in this oldest-old understudied population #olderadults #oldestold #colorectalcancer

https://lnkd.in/ezRdpPc7" Fast-Acting, Sprayable Diagnostic for Real-Time Fluorescence-Guided Cytoreductive Surgery Building on our legacy of innovative targeted diagnostics and therapeutics, Molecular Targeting Technologies,Inc recently reported on its topical, near-infrared fluorescent dye, CypH-11 (#Cmetglo) at the World Molecular Imaging Conference (WMIC) meeting in Montreal and at the Peritoneal Surface Oncology Group International (PSOGI) meeting in Lyon. This technology shows promise as a real-time tool for oncologists in fluorescence-guided surgery (#FGS). Clinicians can see small tumor residue quickly, driving a more complete resection of cancers. #Cmetglo improves patient outcomes, avoiding normal tissue damage and improving progression-free survival. Summarizing comments by Dr. Johnny Ong, MD, Associate Professor, Department of Sarcoma, Peritoneal and Rare Tumors, National Cancer Centre Singapore; Dr. Brian D Gray, SVP Research and Development at MTTI and Dr. Seung Koo Lee, Assistant Professor of Cell Biology Research, in Radiology at Weill Cornell Medicine: “MTTI’s Cmetglo makes the invisible immediately visible. Tumor margins and metastases glow under near-infrared light enhancing a surgeon’s ability to differentiate between normal and scar tissues in cytoreductive surgery (CRS). Cmetglo is a sprayable, pH-responsive probe, fluorescing brightly in an acidic tumor microenvironment, a universal signature of cancer cell proliferation. It readily detects small ovarian and colorectal tumors. We're targeting these malignancies as best clinical use of Cmetglo, later expanding to other histological subtypes.”

Our recent work in Oral Diseases! Textbook outcome in oral cancer! TO could be regarded as a guide for quality improvement ！ The TO rate was 35%. Younger age, subsite in buccal area, Charlson Comorbidity Index Score of 0, higher body mass index, higher hemoglobin, higher albumin, and unilateral ND were associated with TO. 5-year OS was 70.5% in overall TO patients and 49.0% in non-TO patients (HR, 0.47; 95% CI, 0.31–0.70; p < 0.001). …. Conclusion: Not achieving TO in oral cancer surgery was associated with worse long-term outcome. TO could be used as a proxy for surgical quality improvement.